Lasting Effects of a Single Psilocybin Dose on Resting-state Functional Connectivity in Healthy Individuals
Overview
Authors
Affiliations
Background: Psilocybin is a psychedelic drug that has shown lasting positive effects on clinical symptoms and self-reported well-being following a single dose. There has been little research into the long-term effects of psilocybin on brain connectivity in humans.
Aim: Evaluate changes in resting-state functional connectivity (RSFC) at 1 week and 3 months after one psilocybin dose in 10 healthy psychedelic-naïve volunteers and explore associations between change in RSFC and related measures.
Methods: Participants received 0.2-0.3 mg/kg psilocybin in a controlled setting. Participants completed resting-state functional magnetic resonance imaging (fMRI) scans at baseline, 1-week and 3-month post-administration and [11C]Cimbi-36 PET scans at baseline and 1 week. We examined changes in within-network, between-network and region-to-region RSFC. We explored associations between changes in RSFC and psilocybin-induced phenomenology as well as changes in psychological measures and neocortex serotonin 2A receptor binding.
Results: Psilocybin was well tolerated and produced positive changes in well-being. At 1 week only, executive control network (ECN) RSFC was significantly decreased (Cohen's = -1.73, pFWE = 0.010). We observed no other significant changes in RSFC at 1 week or 3 months, nor changes in region-to-region RSFC. Exploratory analyses indicated that decreased ECN RSFC at 1 week predicted increased mindfulness at 3 months ( = -0.65).
Conclusions: These findings in a small cohort indicate that psilocybin affects ECN function within the psychedelic 'afterglow' period. Our findings implicate ECN modulation as mediating psilocybin-induced, long-lasting increases in mindfulness. Although our findings implicate a neural pathway mediating lasting psilocybin effects, it is notable that changes in neuroimaging measures at 3 months, when personality changes are observed, remain to be identified.
Impact of Psilocybin on Peripheral Cytokine Production.
DiRenzo D, Barrett F, Perin J, Darrah E, Christopher-Stine L, Griffiths R Psychedelic Med (New Rochelle). 2025; 2(2):109-115.
PMID: 40051582 PMC: 11658649. DOI: 10.1089/psymed.2023.0039.
Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications.
Melani A, Bonaso M, Biso L, Zucchini B, Conversano C, Scarselli M Pharmaceuticals (Basel). 2025; 18(1).
PMID: 39861191 PMC: 11769142. DOI: 10.3390/ph18010130.
Koning E, Chaves C, Kirkpatrick R, Brietzke E J Eat Disord. 2024; 12(1):214.
PMID: 39731144 PMC: 11673730. DOI: 10.1186/s40337-024-01185-8.
Calder A, Hase A, Hasler G Mol Psychiatry. 2024; 30(2):763-776.
PMID: 39613915 PMC: 11753367. DOI: 10.1038/s41380-024-02830-z.
Psychedelics for the Treatment of Obsessive-Compulsive Disorder: Efficacy and Proposed Mechanisms.
Collins H Int J Neuropsychopharmacol. 2024; 27(12).
PMID: 39611453 PMC: 11635828. DOI: 10.1093/ijnp/pyae057.